Company: STAA
Filing Date: 2025-10-06
Form Type: DEFA14A
Source: 0001193125-25-230935
Chunk: 3

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DEFA14A
Chunk 3
---
 members who are no longer on the STAAR Board and who                                                                             
 did not vote on the Alcon merger are irrelevant; none of those individuals were involved in the Board’s decision to approve Alcon’s compelling, premium cash value of $28 per share. |

| 4. | Broadwood allegation: “Negotiations took place over just one month” |

| • |     | STAAR Response – Broadwood’s statement is inaccurate and misleading |

| • |     | The process was not “rushed” or “truncated.” STAAR engaged in extensive negotiations with 
 Alcon that began in 2024.                                                                 |

| • |     | For more than a year prior to entering into the Alcon agreement, STAAR’s Board conducted an extensive                                                                        
 review of strategic alternatives available to the Company, including considering the Company’s standalone prospects and risks, the industry landscape, and potential buyers. |

Broadwood Allegation of “Wrong Time”

| 1. | Broadwood allegation: “Fundamental performance has been on the upswing” |

| • |     | STAAR Response – Broadwood is ignoring the adverse impact of demand issues and other headwinds |

| • |     | STAAR agrees with Broadwood that management has been effective in reducing selling, general, and administrative 
 expenses, addressing short term tariff issues, and improving gross margin.                                      |

| • |     | More importantly, however, demand issues, which are the primary driver of valuation, remain challenging: |

| • |     | Net sales have been decreasing since 2023. |

| • |     | Net sales decreased 55% and STAAR reported a net loss of $16.8 million in the second quarter of 2025. |

| • |     | Net sales growth has slowed significantly; even if STAAR achieves its 2026 projection of $340 million in net 
 sales, that will only yield a three-year CAGR of 2% from the $322 million in net sales it reported in 2023.  |

| 2. | Broadwood allegation: “STAAR’s challenges are abating” |

| • |     | STAAR Response – Broadwood is misinformed regarding STAAR’s market dynamics |

| • |     | STAAR embraces its EVO ICL technology, as does Broadwood, but STAAR is not naïve to the heightened 
 competitive risks.                                                                                 |

| • |     | STAAR’s primary longer-term challenges are structural and are not abating